Market Overview:
The global candesartan and hydrochlorothiazide market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of hypertension, rising geriatric population, and growing demand for combination therapies. By type, the 16/12.5 segment is expected to account for the largest share of the global candesartan and hydrochlorothiazide market in 2018, followed by the 32/12.5 and 32/25 segments. By application, adults are expected to account for the largest share of the global candesartan and hydrochlorothiazide market in 2018, followed by geriatric patients.
Product Definition:
Candesartan and Hydrochlorothiazide is a medication used to treat high blood pressure. It works by decreasing the amount of water in the body and helping the heart beat more smoothly.
16/12.5:
16/12.5 is a combination of drugs used in the treatment of hypertension and congestive heart failure. It contains two active ingredients, each having half the strength of original medication, which reduces blood pressure by blocking some salt and water retention properties. The combination is more effective than either drug used alone; however, it has more side effects than other medications such as Los Angeles (clarithromycin) or Boston (atorvastin).
32/12.5:
32/12.5 is a type of medical glass that has a diameter of 0.75mm and length of 12.5 mm, it is used in making lenses for ophthalmic (eye) surgery and diagnosis as well as for phototherapy purposes. It can be used with hydrochlorothiazide to make combination drugs called Candesartan which are used to treat hypertension (high blood pressure).
Application Insights:
Adults segment held the largest share of 60.0% in 2017. Candesartan is used for the treatment of hypertension and heart failure in adults. Hypertension is a major concern among most of the adult population globally due to its harmful effects on overall healthiness and quality of life.
Regional Analysis:
North America was the leading market and accounted for over 40% of global candesartan and hydrochlorothiazide market in 2016. In addition, increasing awareness about new products along with rising disposable income is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to be one of the fastest growing regions due to presence of emerging economies such as China & India which are witnessing rapid economic development along with improving healthcare infrastructure at a domestic level.
Growth Factors:
- Increasing prevalence of hypertension and other cardiovascular diseases: The global prevalence of hypertension is estimated to be around 1.13 billion in 2015 and is projected to reach 1.56 billion by 2025. This will create a large pool of patients who will require treatment, thereby driving the demand for candesartan and hydrochlorothiazide market.
- Rising geriatric population: The global geriatric population (aged 65 years or above) is expected to grow from 524 million in 2010 to nearly 1.5 billion by 2050, creating a large pool of patients with age-related health conditions such as hypertension that will require treatment with candesartan and hydrochlorothiazide drugs.
Scope Of The Report
Report Attributes
Report Details
Report Title
Candesartan and Hydrochlorothiazide Market Research Report
By Type
16/12.5, 32/12.5, 32/25
By Application
Adults, Geriatric
By Companies
AstraZeneca, ANI Pharmaceuticals, TEVA, Mylan, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, Prinston Pharmaceutical, MACLEODS, AstraZeneca
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
218
Number of Tables & Figures
153
Customization Available
Yes, the report can be customized as per your need.
Global Candesartan and Hydrochlorothiazide Market Report Segments:
The global Candesartan and Hydrochlorothiazide market is segmented on the basis of:
Types
16/12.5, 32/12.5, 32/25
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adults, Geriatric
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- ANI Pharmaceuticals
- TEVA
- Mylan
- Dr. Reddy's Laboratories
- Zydus Pharmaceuticals
- Prinston Pharmaceutical
- MACLEODS
- AstraZeneca
Highlights of The Candesartan and Hydrochlorothiazide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 16/12.5
- 32/12.5
- 32/25
- By Application:
- Adults
- Geriatric
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Candesartan and Hydrochlorothiazide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Candesartan and hydrochlorothiazide are medications used to treat high blood pressure. Candesartan is a angiotensin receptor blocker (ARB) and hydrochlorothiazide is a diuretic.
Some of the major companies in the candesartan and hydrochlorothiazide market are AstraZeneca, ANI Pharmaceuticals, TEVA, Mylan, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, Prinston Pharmaceutical, MACLEODS, AstraZeneca.
The candesartan and hydrochlorothiazide market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Candesartan and Hydrochlorothiazide Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Candesartan and Hydrochlorothiazide Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Candesartan and Hydrochlorothiazide Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Candesartan and Hydrochlorothiazide Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Candesartan and Hydrochlorothiazide Market Size & Forecast, 2020-2028
4.5.1 Candesartan and Hydrochlorothiazide Market Size and Y-o-Y Growth
4.5.2 Candesartan and Hydrochlorothiazide Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 16/12.5
5.2.2 32/12.5
5.2.3 32/25
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Adults
6.2.2 Geriatric
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Candesartan and Hydrochlorothiazide Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Candesartan and Hydrochlorothiazide Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 16/12.5
9.6.2 32/12.5
9.6.3 32/25
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Adults
9.10.2 Geriatric
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 16/12.5
10.6.2 32/12.5
10.6.3 32/25
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Adults
10.10.2 Geriatric
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 16/12.5
11.6.2 32/12.5
11.6.3 32/25
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Adults
11.10.2 Geriatric
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 16/12.5
12.6.2 32/12.5
12.6.3 32/25
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Adults
12.10.2 Geriatric
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 16/12.5
13.6.2 32/12.5
13.6.3 32/25
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Adults
13.10.2 Geriatric
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Candesartan and Hydrochlorothiazide Market: Competitive Dashboard
14.2 Global Candesartan and Hydrochlorothiazide Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 ANI Pharmaceuticals
14.3.3 TEVA
14.3.4 Mylan
14.3.5 Dr. Reddy's Laboratories
14.3.6 Zydus Pharmaceuticals
14.3.7 Prinston Pharmaceutical
14.3.8 MACLEODS
14.3.9 AstraZeneca
